PETALING JAYA: Pharmaniaga Bhd

’s net profits in its third quarter ended Sept 30 more than tripled to RM26.9mil from RM7.5mil a year earlier, as higher insulin sales and interest savings helped lift earnings.

In a statement, the group said quarterly revenue rose 0.7% to RM1.01bil, mainly on higher insulin sales, while partial repayment of borrowings generated RM3.2mil in interest savings.

For the nine months ended Sept 30, net profits rose 72% to RM72.2mil, while revenue increased 8.2% to RM3.23bil, driven mainly by stronger demand in the concession segment.

Pharmaniaga declared a third interim dividend of 0.32 sen per share for the 2026 financial year (FY26).

Managing director Datuk Zulkifli Jafar said: “Our key business divisions continued to demonstrate resilience and steady progress, supported by sustained demand, operational improvements and ongoing efforts to strengthen our market presence.”

Zulkifli said the increase in the Health Ministry’s allocation to RM47.7bil under Budget 2027, from RM46.5bil in 2026, would support the healthcare sector.

“Against this backdrop, we are strengthening our logistics infrastructure in preparation for the planned expansion of the Approved Products Purchase List (APPL) products to 1,200 by 2030,” he said.

The group said preparatory work at four warehouses was on schedule, with full operations targeted for the first quarter of 2027.

“On the biopharmaceutical front, we have secured National Pharmaceutical Regulatory Agency (NPRA) approvals for two new products, EVnyx and ISENDA,” Zulkifli said.

“Meanwhile, ISENDA (liraglutide) is our first generic glucagon-like peptide-1 (GLP-1) product to cater for type 2 diabetes and weight management in adults and adolescents above 12 years old.”

Pharmaniaga said EVnyx targets hand, foot and mouth disease associated with enterovirus 71. Its collaborations with Indonesia’s PT Bio Farma (Persero) and China’s Yichang HEC Changjiang Pharmaceutical Co Ltd aim to support vaccine and insulin development and technology transfer.

“Building on this momentum, we are also expanding our pharmaceutical portfolio, with nine new products planned for introduction in 2027 across key therapeutic areas, including cardiovascular, oncology, anti-infectives and vaccines, as part of our efforts to broaden our product offerings and address diverse healthcare needs,” Zulkifli said.

“During the year, our distribution subsidiary, PT Millennium Pharmacon International Tbk (PT MPI), successfully secured three new principals and will continue to broaden its product portfolio by appointing additional principals to support revenue growth. We remain committed to improving efficiency, optimising our capital structure and maximising resource utilisation,” he added.